Prevention of cerebral ischemic symptoms in cerebral vasospasm with trapidil, an antagonist and selective synthesis inhibitor of thromboxane A2

Neurosurgery ◽  
1981 ◽  
Vol 9 (6) ◽  
pp. 679???85 ◽  
Author(s):  
S Suzuki ◽  
E Sobata ◽  
T Iwabuchi
Keyword(s):  
Cerebral Vasospasm ◽  
Thromboxane A2 ◽  
Selective Synthesis ◽  
Synthesis Inhibitor ◽  
Cerebral Ischemic

Prevention of Cerebral Ischemic Symptoms in Cerebral Vasospasm with Trapidil, an Antagonist and Selective Synthesis Inhibitor of Thromboxane A2

Neurosurgery ◽  
1981 ◽  
Vol 9 (6) ◽  
pp. 679-685 ◽  
Author(s):  
Shigeharu Suzuki ◽  
Eiji Sobata ◽  
Takashi Iwabuchi
Keyword(s):  
Platelet Aggregation ◽  
Cerebral Ischemia ◽  
Cerebral Vasospasm ◽  
Thrombus Formation ◽  
Cerebral Arteries ◽  
Thromboxane A2 ◽  
Selective Synthesis ◽  
Synthesis Inhibitor ◽  
Symptomatic Vasospasm ◽  
Cerebral Ischemic

Abstract The results of our previous experimental and clinical studies led us to the hypothesis that, in the pathogenesis of cerebral vasospasm, subarachnoid focal acidosis resulting from anaerobic changes of subarachnoid clots may be a factor upsetting the balanced synthesis of both thromboxane A2 and prostaglandin I2 from prostaglandin endoperoxides on the inner surface of cerebral arteries. Thus, there is a higher concentration of thromboxane A2, a prostanoid that causes arterial contraction and platelet aggregation. We tested the administration of trapidil, an antagonist and selective synthesis inhibitor of thromboxane A2, in a series of 20 cases for the prevention of cerebral vasospasm and cerebral ischemia after aneurysmal rupture. Vasospasm was demonstrated by angiography in 9 of these cases, but only 2 of the 9 showed mild signs of cerebral ischemia. Of the 20 patients, 15 were discharged from the hospital as cured and 3 had a neurological deficit at discharge. Our findings suggest the significance in symptomatic vasospasm of thrombus formation by platelet aggregation and the effectiveness of trapidil as a preventive.

Successful 96-Hr cold-storage preservation of canine pancreas with UW solution containing the thromboxane A2 synthesis inhibitor OKY046

1992 ◽  
Vol 52 (6) ◽  
pp. 577-582 ◽  
Author(s):  
Seikon Kin ◽  
Edic Stephanian ◽  
Paul Gores ◽  
Ken Shirabe ◽  
Tsuneo Tanaka ◽  
...  
Keyword(s):  
Cold Storage ◽  
Thromboxane A2 ◽  
Synthesis Inhibitor ◽  
Uw Solution

scholarly journals Beneficial Effect of OKY-046, a Selective Thromboxane A2 Synthetase Inhibitor, on Experimental Cerebral Vasospasm

1986 ◽  
Vol 41 (3) ◽  
pp. 381-391 ◽  
Author(s):  
Hidetada KOMATSU ◽  
Yasuo TAKEHANA ◽  
Shuichiro HAMANO ◽  
Arao UJIIE ◽  
Seiji HIRAKU
Keyword(s):  
Beneficial Effect ◽  
Cerebral Vasospasm ◽  
Thromboxane A2 ◽  
Synthetase Inhibitor ◽  
Thromboxane A2 Synthetase Inhibitor

Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm

Life Sciences ◽  
1997 ◽  
Vol 61 (14) ◽  
pp. 1371-1377 ◽  
Author(s):  
Yoshinori Toshima ◽  
Shin-ichi Satoh ◽  
Ichiro Ikegaki ◽  
Toshio Asano ◽  
Yoshio Suzuki ◽  
...  
Keyword(s):  
Cerebral Vasospasm ◽  
Chronic Phase ◽  
Thromboxane A2 ◽  
Synthetase Inhibitor ◽  
Thromboxane A2 Synthetase Inhibitor

Prevention of cerebral vasospasm by actinomycin D

1991 ◽  
Vol 74 (6) ◽  
pp. 940-943 ◽  
Author(s):  
Taku Shigeno ◽  
Tatsuo Mima ◽  
Masashi Yanagisawa ◽  
Akira Saito ◽  
Katsutoshi Goto ◽  
...  
Keyword(s):  
Cerebral Vasospasm ◽  
Ribonucleic Acid ◽  
Actinomycin D ◽  
Acid Synthesis ◽  
Experimental Therapy ◽  
Synthesis Inhibitor ◽  
Content Type ◽  
Messenger Ribonucleic Acid ◽  
Experimental Subarachnoid Hemorrhage

✓ The role of endothelin, a newly found vasoconstrictor peptide, is examined in the pathogenesis of cerebral vasospasm after experimental subarachnoid hemorrhage (SAH) in the dog. Endothelin immunoreactivity was overexpressed in the endothelium of the vasospastic basilar artery. Because endothelin synthesis is regulated at the messenger ribonucleic acid transcription level, the effect of actinomycin D, a ribonucleic acid synthesis inhibitor, was studied as a means of preventing vasospasm. It was found that treatment with intravenous actinomycin D for 5 days beginning on the day of SAH completely inhibited the development of vasospasm. This novel experimental therapy may lead not only to the elucidation of the pathogenesis of cerebral vasospasm but also to the availability of a prophylactic adjuvant therapy for patients with SAH.

scholarly journals Effect of selective inhibitor of thromboxane A2 synthetase on experimental cerebral vasospasm.

Stroke ◽  
1984 ◽  
Vol 15 (2) ◽  
pp. 306-311 ◽  
Author(s):  
T Fukumori ◽  
E Tani ◽  
Y Maeda ◽  
A Sukenaga
Keyword(s):  
Cerebral Vasospasm ◽  
Thromboxane A2 ◽  
Selective Inhibitor
Sign in / Sign up

Export Citation Format

Share Document